Showing results (21-30 of 266) with videos related to
Sort By:
Pageof 27
Proceedings of the National Academy of Sciences of the United States of America|February 16, 2007
Proteomics of specific treatment-related alterations in Fabry disease: a strategy to identify biological abnormalitiesDavid F Moore, Oleg V Krokhin, Ronald C Beavis, et al.Molecular Genetics and Metabolism|December 28, 2005
Childhood ataxia with CNS hypomyelination/vanishing white matter disease--a common leukodystrophy caused by abnormal control of protein synthesisRaphael Schiffmann, Orna Elroy-SteinThe Lancet. Neurology|November 24, 2004
Enzyme-replacement therapy for metabolic storage disordersRoscoe O Brady, Raphael SchiffmannDrugs|April 4, 2002
New prospects for the treatment of lysosomal storage diseasesRaphael Schiffmann, Roscoe O BradyJournal of Inherited Metabolic Disease|March 19, 2017
Enzyme replacement therapy and beyond-in memoriam Roscoe O. Brady, M.D. (1923-2016)Markus RiesFrontiers in Public Health|October 3, 2022
Global key concepts of civil-military cooperation for disaster management in the COVID-19 pandemic-A qualitative phenomenological scoping reviewMarkus RiesThe Journal of Pediatrics|January 26, 2010
Four-year prospective clinical trial of agalsidase alfa in children with Fabry diseaseRaphael Schiffmann, Rick A Martin, Tyler Reimschisel, et al.Journal of the American Society of Nephrology : JASN|April 10, 2009
Agalsidase alfa and kidney dysfunction in Fabry diseaseMichael West, Kathy Nicholls, Atul Mehta, et al.Neurology. Genetics|April 29, 2016
Long-term follow-up and sudden unexpected death in Gaucher disease type 3 in EgyptMagy Abdelwahab, Derek Blankenship, Raphael SchiffmannAnnals of Neurology|December 11, 2008
Randomized, controlled trial of miglustat in Gaucher's disease type 3Raphael Schiffmann, Edmond J Fitzgibbon, Chris Harris, et al.Pageof 27